{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:00:01Z","timestamp":1769846401940,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.14219\/jada.archive.2008.0017","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:43:42Z","timestamp":1389228222000},"page":"32-40","source":"Crossref","is-referenced-by-count":92,"title":["Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial"],"prefix":"10.1016","volume":"139","author":[{"given":"John T.","family":"Grbic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Landesberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mesenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Chung","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Recknor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik F.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.14219\/jada.archive.2008.0017_bib2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study","volume":"50","author":"Leibson","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.14219\/jada.archive.2008.0017_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","article-title":"Excess mortality after hospitalisation for vertebral fracture","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporosis Int"},{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","article-title":"Mortality after osteoporotic fractures","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.14219\/jada.archive.2008.0017_bib5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"24","key":"10.14219\/jada.archive.2008.0017_bib6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.14219\/jada.archive.2008.0017_bib7","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial (published correction appears in J Clin Endocrinol Metab 2001;86[2]:938.)","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.14219\/jada.archive.2008.0017_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.14219\/jada.archive.2008.0017_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.14219\/jada.archive.2008.0017_bib11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.14219\/jada.archive.2008.0017_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.smj.0000221637.90495.66","article-title":"Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting","volume":"99","author":"Downey","year":"2006","journal-title":"South Med J"},{"issue":"8","key":"10.14219\/jada.archive.2008.0017_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.14219\/jada.archive.2008.0017_bib14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"10.14219\/jada.archive.2008.0017_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.14219\/jada.archive.2008.0017_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggerio","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"10.14219\/jada.archive.2008.0017_bib17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"issue":"22","key":"10.14219\/jada.archive.2008.0017_bib18","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphonates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.mlg.0000187398.51857.3c","article-title":"Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates","volume":"116","author":"Farrugia","year":"2006","journal-title":"Laryngoscope"},{"issue":"4","key":"10.14219\/jada.archive.2008.0017_bib20","first-page":"268","article-title":"Bisphosphonates and avascular necrosis of the jaws","volume":"48","author":"Carter","year":"2003","journal-title":"Aust Dent J"},{"issue":"3","key":"10.14219\/jada.archive.2008.0017_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"46","key":"10.14219\/jada.archive.2008.0017_bib22","first-page":"3078","article-title":"Onkologie: Kiefernekrosen nach hoch dosierter Bisphosphonattherapie","volume":"103","author":"Felsenberg","year":"2006","journal-title":"Deutsches \u00c4rzteblatt"},{"issue":"10","key":"10.14219\/jada.archive.2008.0017_bib23","first-page":"801","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"35","author":"Sambrook","year":"2006","journal-title":"Aust Fam Physician"},{"issue":"8","key":"10.14219\/jada.archive.2008.0017_bib24","first-page":"1144","article-title":"Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations","volume":"137","author":"American Dental Association Council on Scientific Affairs","year":"2006","journal-title":"JADA"},{"issue":"3","key":"10.14219\/jada.archive.2008.0017_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"issue":"3","key":"10.14219\/jada.archive.2008.0017_bib27","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.14219\/jada.archive.2008.0017_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"18 supplement","key":"10.14219\/jada.archive.2008.0017_bib29","first-page":"475S","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract 8528)","volume":"24","author":"Hoff","year":"2006","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.14219\/jada.archive.2008.0017_bib30","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.14219\/jada.archive.2008.0017_bib31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.14219\/jada.archive.2008.0017_bib32","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"10.14219\/jada.archive.2008.0017_bib33","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"issue":"supplement 2","key":"10.14219\/jada.archive.2008.0017_bib34","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0960-9776(03)80161-3","article-title":"The anti-tumor potential of zoledronic acid","volume":"12","author":"Croucher","year":"2003","journal-title":"Breast"},{"key":"10.14219\/jada.archive.2008.0017_bib35","first-page":"1256","article-title":"The bisphosphonate rise-dronate inhibits both angiogenesis and bone metastasis formation in vivo","volume":"44","author":"Fournier","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"5","key":"10.14219\/jada.archive.2008.0017_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9\u2013expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"issue":"10","key":"10.14219\/jada.archive.2008.0017_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1902\/jop.1992.63.10.825","article-title":"Effects of a bisphosphonate on experimental periodontitis in monkeys","volume":"63","author":"Brunsvold","year":"1992","journal-title":"J Periodontol"},{"issue":"1","key":"10.14219\/jada.archive.2008.0017_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0765.1994.tb01088.x","article-title":"Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys","volume":"29","author":"Weinreb","year":"1994","journal-title":"J Periodontal Res"},{"issue":"3","key":"10.14219\/jada.archive.2008.0017_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1902\/jop.1995.66.3.211","article-title":"Alendronate treatment of naturally-occurring periodontitis in beagle dogs","volume":"66","author":"Reddy","year":"1995","journal-title":"J Periodontol"},{"issue":"4","key":"10.14219\/jada.archive.2008.0017_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0765.1995.tb02134.x","article-title":"Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats","volume":"30","author":"Shoji","year":"1995","journal-title":"J Periodontal Res"},{"issue":"4","key":"10.14219\/jada.archive.2008.0017_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-0765.1998.tb02191.x","article-title":"Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs","volume":"33","author":"O'uchi","year":"1998","journal-title":"J Periodontal Res"},{"issue":"2","key":"10.14219\/jada.archive.2008.0017_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0501.2001.012002109.x","article-title":"Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs","volume":"12","author":"Shibutani","year":"2001","journal-title":"Clin Oral Implants Res"},{"issue":"10","key":"10.14219\/jada.archive.2008.0017_bib43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714614070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714614070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T13:20:16Z","timestamp":1538918416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817714614070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0002817714614070"],"URL":"https:\/\/doi.org\/10.14219\/jada.archive.2008.0017","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}